Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 443 M
EBIT 2017 28,9 M
Net income 2017 -20,3 M
Finance 2017 319 M
Yield 2017 -
Sales 2018 518 M
EBIT 2018 41,7 M
Net income 2018 24,4 M
Finance 2018 447 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 135,99
EV / Sales2017 14,6x
EV / Sales2018 12,2x
Capitalization 6 790 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology.It operates its business through the Ionis Core and Akcea Therapeutics segments.The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline... 
Sector
Biotechnology & Medical Research
Calendar
12/14 | 07:30pmPresentation
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
12/07 IONIS PHARMACEUTICALS : to Present at the BMO Capital Markets 2017 Prescriptions..
12/05 IONIS PHARMACEUTICALS INC : Today’s Research Reports on Stocks to Watch: Ionis P..
11/30 IONIS PHARMACEUTICALS : Researchers Submit Patent Application, "Method for Solut..
11/20 IONIS PHARMACEUTICALS : Licenses Second Orally Delivered Antisense Drug to Janss..
11/17 AKCEA THERAPEUTICS : and Ionis Announce Acceptance of Marketing Applications in ..
11/16 IONIS PHARMACEUTICALS : Announces Submission of New Drug Application NDA for Ino..
11/16 IONIS PHARMACEUTICALS : Licenses Second Orally Delivered Antisense Drug to Janss..
11/16 AKCEA THERAPEUTICS : and Ionis Announce Acceptance of Marketing Applications in ..
11/15 AKCEA THERAPEUTICS : Initiates -ANGPTL3-LRx Phase 2 Program in Patients with Rar..
11/14 IONIS PHARMACEUTICALS : Licenses Novel Antisense Drug for the Treatment of Centr..
More news
Sector news : Biotechnology & Medical Research - NEC
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
ISIS PHARMACEUTICALS - 2014
A resistance as obstacle
SELL
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 14
Average target price 57,0 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Inside Director
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
Joseph H. Wender Independent Outside Director
Frederick T. Muto Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 790
CELLTRION, INC.--.--%22 034
IQVIA HOLDINGS INC32.81%21 333
INCYTE CORPORATION-6.46%20 382
LONZA GROUP54.74%19 270
ALNYLAM PHARMACEUTICALS, INC.239.21%12 871